Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Condition: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Sponsor: Peking University People's Hospital
About this study
To evaluate the efficacy and safety of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed or refractory B-ALL
This description comes directly from the study's public registry record.
Talk to the study team
MENG LV, MD, PhD · +861088324637 · drlvmeng@bjmu.edu.cn
Always discuss trial participation with your own doctor first.
Locations (1)
| Deparment of Hematology, Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06880913